Matteo Nguyen

Where does it fail? The single point of failure lies in simply publishing a research framework on arXiv, even with innovative techniques, which does not constitute sufficient operational proof to directly influence Series A funding decisions.
The weakest link is the transition between academic prediction and practical application, requiring rigorous empirical validation and independent audits to be accepted by investors and regulators.
Without a verifiable performance history and clear mechanisms for integration into due diligence processes, the Japanese FSA would consider this framework as an intellectual exercise.
For example, a model predicting success without tangible evidence of market traction or risk management will carry little weight in a real funding decision.

Where does it fail? The weakest link in this statement is translating theory into concrete practice for Series A funding.
A research paper, no matter how innovative, does not guarantee investors' conviction or regulatory compliance.
In Japan, the FSA requires tangible evidence of commercial viability and risk management, not just theoretical models.
Without robust empirical validation under real market conditions and adoption by venture capital actors, the impact on Series A funding remains purely academic.
For example, a Japanese venture capital fund will not invest solely based on an arXiv model; it will require traction evidence and a solid business plan.

Where does it fail? The idea that an arXiv article on the MIRAGE-VC framework "informs" directly the obtaining of Series A funding is an oversimplification that ignores market mechanisms.
The failure mode is the jump between academic publication and practical validation without concrete proof of actual performance.
In Japan, institutional investors, influenced by funds like the GPIF, require thorough due diligence and tangible evidence of commercial viability before committing capital.
A predictive model only becomes relevant after demonstrating its ability to generate consistent and auditable results in real conditions, for example by validating its predictions with market data post-publication or proving its utility via POC with established VCs.

Where does it fail? The idea that a simple research publication directly informs Series A funding overestimates the scope. The reality is that the mechanism breaks if the underlying data of the model do not reflect the unique conditions of the Japanese market, including cultural preferences for established relationships. It does not account for the local risk aversion that often takes precedence over predictive models; for example, a Japanese venture capital fund might prefer a project with an established collaboration history rather than a high predictive score.

Let's debunk the hype: publishing a research article on arXiv does nothing to change the actual cash flow for obtaining Series A funding.
For venture capital actors, what matters are the concrete evidence of traction and viability of a company, not theoretical models, no matter how sophisticated.
The AMF, for example, would require independent audits and robust empirical validation before such a framework influences investment decisions.
Without this, a model like MIRAGE-VC remains an intellectual exercise, lacking persuasive power over an investor.
For example, a success prediction without understanding the risks specific to a project will be ignored.